Compare Danaher Corporation (DHR) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Paychex, Inc. — how do they compare? Danaher Corporation trades at $200.27 (market cap $140.88B), while Paychex, Inc. trades at $111.78 (market cap $38.95B). The key difference: Danaher Corporation is far larger — about 3.6× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.35%). Which is the better fit depends on your goals.
| DHR | PAYX | |
|---|---|---|
Market Cap | $140.88B | $38.95B |
Sector | Health | Industrials |
52-Week High | $242.05 | $147.99 |
52-Week Low | $161.91 | $85.57 |
Enterprise Value | $153.66B | $42.43B |
Dividend Yield | 0.8% | 4.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Paychex (PAYX) trades at $110.75, up 2.98% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations, and maintains robust profitability with 27.03% net income margin. Recent dividend payment of $1.19 and positive business momentum from AI expansion and small business hiring trends support growth outlook.
Outlook remains positive with steady revenue growth and AI-driven efficiency gains, though valuation multiples appear elevated with P/E of 22.65. Risks include competitive pressures and macroeconomic sensitivity to small business employment trends. Analyst consensus is mixed with 16.67% buy ratings but price target alignment with current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
